Wegovy Through Hims vs Ro: Cost, Eligibility, and Delivery Compared

Wegovy is the FDA-approved branded version of semaglutide for weight loss, manufactured by Novo Nordisk. Both Hims and Ro can prescribe branded Wegovy through their weight-loss programs and coordinate delivery via partner pharmacies. The medication itself is the same – Novo Nordisk’s manufacturer-set pricing applies regardless of which platform writes the prescription. The differences between Hims and Ro for Wegovy specifically come down to program fees, insurance navigation, and the wraparound clinical experience. This wegovy hims vs ro comparison breaks down 2026 costs, eligibility screening, and delivery logistics. The short version: medication cost is set by Novo Nordisk and similar at both platforms; program fees and clinical experience are the real variables. Prices and program terms change often, so verify current details directly before relying on any figure here.

Wegovy pricing – set by Novo Nordisk

Wegovy’s list price is roughly $1,349 per month (per 28-day package) at Novo Nordisk’s manufacturer pricing. With insurance covering Wegovy for FDA-approved indications, your out-of-pocket cost depends on plan formulary, prior authorization status, and copay structure – often somewhere in the range of $25 to $150 per month for covered patients, though this varies widely.

Without insurance, self-pay patients can often access Wegovy through Novo Nordisk’s NovoCare Pharmacy direct-to-patient channel. As of the latest check, the self-pay cash price for the Wegovy pen was around $349 per month for standard doses (with a limited-time introductory rate of about $199 per month for the first couple of months at the lowest starting doses for new patients). Novo has also introduced lower-cost oral options. These self-pay figures have come down from earlier levels and can change again – confirm the current price on NovoCare before assuming any number.

This pricing applies regardless of whether the prescription is written through Hims, Ro, a primary care doctor, or a bariatric medicine specialist. The platform does not change the medication’s underlying cost.

Hims vs Ro program fees on top of Wegovy

Beyond the medication cost, each platform adds its own program or membership fees. The figures below are approximate and promotional pricing shifts frequently, so treat them as a general guide and confirm at signup:

Hims weight loss (approximate):

• Initial visit fee in the tens of dollars
• Ongoing monthly program cost that varies by plan
• Promotional pricing often available at signup

Ro Body weight loss (approximate):

• Initial visit fee in the tens of dollars
• A defined monthly membership
• Includes clinician access, lab-work review, and ongoing prescription management

For Wegovy patients, the program fee is added on top of the medication cost (list price or whatever discounted/self-pay price applies). Because the drug cost dominates the total, the difference in platform fees is relatively small in the context of a branded-Wegovy bill. See our individual Hims review and Ro review for more detail, and verify current fees on each platform.

Eligibility screening – both follow FDA labeling

Both platforms screen for Wegovy eligibility per FDA labeling: generally a BMI of 27 or higher with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, hyperlipidemia, or obstructive sleep apnea), or a BMI of 30 or higher without a comorbidity. There is also an adolescent indication (ages 12 and up) that follows a separate clinical pathway. Eligibility is ultimately a clinical determination made by the prescribing clinician – not something to self-diagnose.

Contraindications and cautions screened at both platforms include:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis
• Pregnancy, planning pregnancy, or breastfeeding
• Severe gastrointestinal disease including gastroparesis
• Serious kidney or liver concerns

The screening is appropriately conservative at both platforms. Patients with contraindications are screened out and may be offered alternatives where clinically appropriate. If you have any of these conditions, or are unsure, discuss it with a clinician before starting – this is not a decision to make from an online questionnaire alone.

Insurance coordination – broadly similar at both

Neither Hims nor Ro bills insurance for the visit or program fee. Both can coordinate Wegovy prescriptions with your insurance for medication coverage, but much of the legwork is patient-driven. Prior authorization is typically required for Wegovy coverage and can be onerous.

For patients with strong commercial insurance that covers Wegovy without restrictive prior-authorization requirements, both platforms produce similar total costs. For patients facing restrictive requirements, the experience varies – neither platform guarantees prior-authorization approval, and both may require multiple submissions.

Some patients use a platform to obtain a Wegovy prescription and then transfer it to a local in-network pharmacy where insurance handles the medication directly. This is generally permissible at both platforms; confirm the process with the platform and your pharmacy.

Pharmacy delivery and supply

Both platforms coordinate Wegovy delivery through partner pharmacies. Ro operates Ro Pharmacy directly; Hims works with affiliated pharmacies. Wegovy supply was intermittently constrained after launch, with availability varying by dose strength.

Lower titration doses were historically more prone to shortage than the maintenance dose. After the FDA declared the semaglutide shortage resolved in 2025, branded Wegovy supply generally stabilized. Availability can still vary by dose and pharmacy, so confirm current stock and expected delivery timing when you order.

Compounded semaglutide alternatives – largely phased out

Through 2024, both Hims and Ro (and many other telehealth providers) offered compounded semaglutide as a cheaper alternative to branded Wegovy, priced well below the branded list price. That changed in 2025.

Once the FDA determined the semaglutide shortage was resolved in 2025, the legal basis for large-scale compounding of semaglutide wound down, and platforms phased out most compounded options. As of 2026, compounded semaglutide is largely unavailable through these platforms for new patients. Patients seeking lower-cost semaglutide now generally look at branded Wegovy with savings/self-pay programs, switch to a different medication class, or explore options with a clinician. Be cautious of sources still marketing cheap compounded GLP-1s, as the regulatory landscape has shifted and product quality outside FDA-approved channels is not assured.

The Hims-Novo relationship and the move to branded GLP-1s

The commercial relationships in this space have shifted meaningfully. In 2025, a short-lived arrangement that let Hims offer branded Wegovy in collaboration with Novo Nordisk ended publicly, amid disputes over compounding and marketing practices. Reporting in early 2026 pointed to a subsequent resolution/settlement between the parties, with the platforms emphasizing branded, FDA-approved GLP-1 access rather than compounded products. The details of these arrangements have moved quickly and may have changed again – treat this as background and verify the current state of any partnership, pricing, and product availability directly with the platform before making decisions.

The practical takeaway for consumers: as of 2026, the focus at both Hims and Ro is on branded, FDA-approved GLP-1 medications (such as Wegovy), obtained under a prescriber’s direction, rather than on compounded semaglutide.

The Ozempic question

Some patients ask about Ozempic specifically rather than Wegovy. Ozempic is the same active ingredient (semaglutide) at different dose strengths, FDA-approved for type 2 diabetes rather than for weight loss. Off-label Ozempic prescribing for weight loss is possible in principle but has become less common as Wegovy is FDA-approved for that use and insurance coverage has shifted accordingly.

Neither Hims nor Ro typically prescribes off-label Ozempic for weight loss in 2026. For patients with type 2 diabetes plus obesity, Ozempic prescribed for the diabetes indication may produce weight loss as a beneficial effect, but that is generally handled through primary care or endocrinology rather than a direct-to-consumer weight-loss platform. Discuss the right medication and indication with your clinician.

Specific use cases – when each platform may suit you

Hims may suit you if: promotional pricing at signup is favorable, you already use Hims (or Hers, which shares infrastructure) for other health needs, or you prefer its program structure.

Ro may suit you if: you prefer a clearly defined monthly membership, you already use Ro for other needs, or its clinical experience appeals to you.

Neither may be necessary if: you have strong insurance coverage for Wegovy and can obtain the prescription through a primary care doctor or in-person bariatric medicine clinic – the platform fee is avoidable if insurance handles the medication directly. There is no single “best” choice; it depends on your coverage, budget, and preferences.

Frequently Asked Questions

Is Wegovy through Hims the same as through Ro?

Yes. Both platforms dispense the same branded Wegovy from Novo Nordisk. The medication is identical regardless of which platform writes the prescription; the differences are in fees and service.

Why is Wegovy so expensive?

Novo Nordisk sets Wegovy’s list price at roughly $1,349 per month (per 28-day package). Insurance, savings programs, and self-pay channels like NovoCare can reduce out-of-pocket cost for eligible patients – verify current pricing directly.

Can I get cheaper Wegovy through Hims or Ro?

The medication price is set by Novo Nordisk and is similar across platforms. Neither platform substantially discounts branded Wegovy itself; the difference between them is primarily in program fees. Novo’s own self-pay channel may be the lower-cost route for uninsured patients.

Do both platforms handle Wegovy insurance prior authorization?

Both can coordinate prior-authorization submissions, but neither guarantees approval. Prior-authorization decisions are insurer-driven and can be onerous regardless of which platform handles the prescription.

Are there cheaper Wegovy alternatives through these platforms?

Compounded semaglutide has largely been phased out following the 2025 shortage resolution. Both platforms may offer other branded FDA-approved options such as Zepbound (tirzepatide), which has broadly comparable pricing. Discuss which medication is appropriate with your clinician.

The bottom line on Wegovy through Hims vs Ro

For Wegovy specifically, Hims and Ro are largely interchangeable. The medication is the same – Novo Nordisk’s branded Wegovy at manufacturer pricing – so the drug cost dominates the total either way. Program fees differ modestly, and the clinical experience and membership structure differ in feel more than substance. Insurance navigation, eligibility screening, and pharmacy delivery are broadly similar. Choose based on which platform’s current pricing fits your situation, which you may already use, and your preferences. For patients with strong insurance coverage, working directly with a primary care doctor or bariatric medicine specialist may eliminate the need for either platform’s program fee. Whatever route you choose, eligibility and dosing are clinical decisions – work them out with a licensed clinician, and verify all current pricing and terms before committing.

Sources

• Novo Nordisk / NovoCare – Wegovy list price and self-pay pricing (novocare.com)
• U.S. Food & Drug Administration – semaglutide shortage resolution and compounding guidance (fda.gov)
• Wegovy Prescribing Information / FDA label – indications and contraindications (accessdata.fda.gov)